A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers - PubMed (original) (raw)

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers

Stephanie M Cohen et al. Am J Surg. 2012 Dec.

Abstract

Background: Sorafenib (SO), a multikinase-targeted inhibitor in clinical trials for papillary and anaplastic cancers, shows limited efficacy with moderate toxicity. Withaferin A (WA), a natural withanolide, shows potent preclinical anticancer activity in thyroid cancers through multiple cytotoxic mechanisms including heat-shock protein inhibition. We hypothesized that combination therapy (WA + SO) would have a synergistic effect against anaplastic and papillary carcinoma cells at lower sorafenib doses.

Methods: Human papillary (BCPAP) and anaplastic (SW1736) thyroid cancer cell lines were evaluated after treatment with SO, WA, or their combination at different doses. Proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and trypan blue exclusion; apoptosis and cell-cycle arrest was measured by flow cytometry. Western analysis confirmed apoptosis (Poly ADP ribose polymerase [PARP] and caspase-3 cleavage) and Raf inhibition. Experiments were repeated in triplicate and were evaluated statistically with significance set at a P value of less than .05.

Results: The concentration of drug at which 50% of the cells are inhibited (IC(50)) in BCPAP were 6.3 μmol/L (SO), .155 μmol/L (WA), and .055 μmol/L (IC(50)WA + 50% IC(50)SO), whereas in SW1736 cells the concentration was 7.6 μmol/L (SO), 2.5 μmol/L (WA), and 1.4 μmol/L (IC(50)WA + 50% IC(50)SO). Combination (WA + SO) at IC(50) decreased cell viability to 19% (from 50% individually). Apoptosis levels on flow cytometry in anaplastic cells increased significantly from 0% to 2% (SO or WA alone) to 89% (combo at IC(50), P < .001). Combination therapy apoptosis (PARP cleavage and caspase-3 inactivation) and BRAF/Raf-1 down-regulation were dose-dependent starting at 50% IC(50) levels. Cell-cycle modulation was significant with combination treatment (35% increase in G2 arrest at 50% IC(50)SO + WA and 70% increase at 75% IC(50)SO + WA; P < .01).

Conclusions: Combination therapy with sorafenib + withaferin showed synergistic efficacy in papillary and anaplastic cancers in vitro with significant induction of apoptosis. This combination achieved potent anticancer activity with lower overall doses of sorafenib, indicating a potential strategy to decrease sorafenib toxicity in future translational studies.

PubMed Disclaimer

Cited by

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
Ryu H, Choi HK, Kim HJ, Kim AY, Song JY, Hwang SG, Kim JS, Kim DU, Kim EH, Kim J, Ahn J. Ryu H, et al. Int J Mol Sci. 2019 Sep 24;20(19):4728. doi: 10.3390/ijms20194728. Int J Mol Sci. 2019. PMID: 31554189 Free PMC article.
Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives.
Behl T, Sharma A, Sharma L, Sehgal A, Zengin G, Brata R, Fratila O, Bungau S. Behl T, et al. Biomedicines. 2020 Dec 6;8(12):571. doi: 10.3390/biomedicines8120571. Biomedicines. 2020. PMID: 33291236 Free PMC article. Review.
Withaferin A: From Ancient Remedy to Potential Drug Candidate.
Sultana T, Okla MK, Ahmed M, Akhtar N, Al-Hashimi A, Abdelgawad H, Haq IU. Sultana T, et al. Molecules. 2021 Dec 20;26(24):7696. doi: 10.3390/molecules26247696. Molecules. 2021. PMID: 34946778 Free PMC article. Review.
The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.
Abeesh P, Guruvayoorappan C. Abeesh P, et al. Curr Mol Med. 2024;24(4):404-418. doi: 10.2174/1566524023666230418094708. Curr Mol Med. 2024. PMID: 37076466 Review.
FOXE1 Gene Dosage Affects Thyroid Cancer Histology and Differentiation In Vivo.
Credendino SC, Moccia C, Amendola E, D'Avino G, Di Guida L, Clery E, Greco A, Bellevicine C, Brunetti A, De Felice M, De Vita G. Credendino SC, et al. Int J Mol Sci. 2020 Dec 22;22(1):25. doi: 10.3390/ijms22010025. Int J Mol Sci. 2020. PMID: 33375029 Free PMC article.

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers - PubMed (original) (raw)